Dynamic scientist with 15 years of industry experience in successfully navigating the intricate drug development process to advance therapies for multisystemic hereditary diseases from laboratory research to clinical trials. Skilled in the development and execution of research and IND-enabling strategies for lipid nanoparticle based RNA therapies, small molecules, and biologics. Founder of a clinical stage rare disease company. Experienced in leading early-stage biotech operations, developing strategic plans, building highly efficient teams, and securing venture capital funding. Possesses a deep understanding of both established and emerging biotechnologies, along with their associated challenges and market potential.